Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 May;42(5):560-72.
doi: 10.1016/j.biocel.2010.01.004. Epub 2010 Jan 11.

Mitochondrial medicine for neurodegenerative diseases

Heng Du  1 , Shirley ShiDu Yan
Affiliations
Review

Mitochondrial medicine for neurodegenerative diseases

Heng Du et al. Int J Biochem Cell Biol. 2010 May.

Abstract

Mitochondrial dysfunction has been reported in a wide array of neurological disorders ranging from neuromuscular to neurodegenerative diseases. Recent studies on neurodegenerative diseases have revealed that mitochondrial pathology is generally found in inherited or sporadic neurodegenerative diseases and is believed to be involved in the pathophysiological process of these diseases. Commonly seen types of mitochondrial dysfunction in neurodegenerative diseases include excessive free radical generation, lowered ATP production, mitochondrial permeability transition, mitochondrial DNA lesions, perturbed mitochondrial dynamics and apoptosis. Mitochondrial medicine as an emerging therapeutic strategy targeted to mitochondrial dysfunction in neurodegenerative diseases has been proven to be of value, though this area of research is still at in its early stage. In this article, we report on recent progress in the development of several mitochondrial therapies including antioxidants, blockade of mitochondrial permeability transition, and mitochondrial gene therapy as evidence that mitochondrial medicine has promise in the treatment of neurodegenerative diseases.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schematic figure of therapeutic strategies to protect mitochondria against neurodegeneration. In neurodegenerative diseases such as AD, PD, HD and ALS, mitochondria undergo increased ROS production, suppressed respiratory function, mtDNA lesions, mPTP formation, preapoptotic factors release and damaged dynamics/motility. These deleterious factors will eventually lead to neurodegeneration. Mitochondrial medicine, including oxidant scavenge, mPTP inhibition, mitochondrial gene therapy, anti-apoptosis and mitochondrial dynamics modulation, are promising therapeutic strategies to attenuate neurodegeneration and to halt the progression of neuronal injury in the neurodegenerative diseases.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abou-Sleiman PM, Muqit MM, McDonald NQ, Yang YX, Gandhi S, Healy DG, et al. A heterozygous effect for PINK1 mutations in Parkinson’s disease? Ann Neurol. 2006;60:414–9. - PubMed
    1. Adlam VJ, Harrison JC, Porteous CM, James AM, Smith RA, Murphy MP, et al. Targeting an antioxidant to mitochondria decreases cardiac ischemia–reperfusion injury. FASEB J. 2005;19:1088–95. - PubMed
    1. Alam M, Schmidt WJ. Mitochondrial complex I inhibition depletes plasma testosterone in the rotenone model of Parkinson’s disease. Physiol Behav. 2004;83:395–400. - PubMed
    1. Albers DS, Augood SJ, Park LC, Browne SE, Martin DM, Adamson J, et al. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J Neurochem. 2000;74:878–81. - PubMed
    1. Albers DS, Beal MF. Mitochondrial dysfunction in progressive supranuclear palsy. Neurochem Int. 2002;40:559–64. - PubMed

Publication types

MeSH terms

Substances